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Summary 
Signaling through the cell surface molecule, CD40, is known to play an important role in the 
proliferation and differentiation of  B lymphocytes. Using the thymoma  cell line EL4, we recently 
identified and cloned a cDNA encoding a routine ligand for the CD40 molecule (mCD40-L) 
and showed that it has biological activity in vitro. A cDNA encoding a human homologue of 
the mCD40-L was isolated using crosshybridization techniques from an activated peripheral blood 
T cell library. The predicted amino acid sequence indicates that this human ligand for CD40 
(hCD40-L) is a 261 amino acid type II membrane protein that exhibits 78% amino acid identity 
with its murine counterpart. Northern blot and FACS  |  analyses suggest that the hCD40-L is 
restricted  in its expression to T  lymphocytes,  and that it is most abundant on the CD4 + T 
cell subpopulation.  Cells transfected with hCD40-L caused the proliferation  of human tonsil 
B cells in the absence of costimuli and, in the presence of interleukin 4, induced immunoglobulin 
E secretion  from purified human B cells. A comparison of  the efficacy  of  the hCD40-L and mCD40-L 
in these assays is presented. 
C 
D40 is a cell surface protein expressed on B lympho- 
cytes, follicular dendritic cells, normal epithelium, and 
some epithelial carcinomas. The predicted amino acid sequence 
for CD40 indicates that it is a member of the recently de- 
scribed TNF receptor family of proteins  (1-3).  This family 
includes such molecules as the low affinity receptor for nerve 
growth factor, both forms of TNF receptors, CD27, OX40, 
and the Hodgkin's lymphoma marker CD30 (3, 4). In addi- 
tion to structural homology to known cytokine receptors, 
functional effects in B cells have been shown to be mediated 
through mAbs directed against CD40. These effects include 
short- and long-term proliferation  (5-7), differentiation  (8, 
9), induction of intercellular adhesion (10, 11), and tyrosine 
phosphorylation of a series of intracellular proteins (12). Fur- 
thermore, germinal center centrocytes are prevented from un- 
dergoing apoptosis  when activated through their antigen 
receptors and by CD40 mAb (13). Taken together, these data 
strongly suggested that CD40 was the receptor for an un- 
known ligand. 
Recently, we reported the molecular cloning of a ligand 
for CD40  from the murine thymoma cell line EL-4, and 
showed that this ligand was biologically active on primary 
B lymphocytes (14). Cells transfected with mCD40-L could 
induce the proliferation of murine and human B cells in the 
absence of costimuli.  In this paper, we detail the cloning of 
a human homologue of the ligand for CD40; describe the 
relationship  of the nucleotide and predicted amino acid se- 
quences of the hCD40-L with those of the mCD40-L; ex- 
amine the cellular distribution of the hCD40-L by Northern 
blot analysis and cell surface expression; compare the prolifer- 
ative activity of  both the hCD40-L and mCD40-L on human 
tonsillar and murine splenic B cells in the presence and ab- 
sence of  costimuli; and evaluate the ability of the two ligands 
to induce IgE secretion from IL-4-activated B cells. 
Materials and Methods 
Cell Separation.  PBMC  were  purified from healthy donors by 
centrifugation  over Histopaque  |  (Sigma Chemical  Co., St. Louis, 
MO). Peripheral  blood T cells (PB T)  1  were  then purified  by roset- 
ring with 2-aminoethylisothiouronium  bromide (AET)-treated 
SRBC and further  centrifugation  over  Histopaque  |  Contaminating 
monocytes  were  removed  by plastic adherence  for 1 h at 37~  The 
resulting T cell preparations were  always  >98% CD3 §  as deter- 
mined by flow cytometric  analysis (FACScan  |  Becton Dickinson 
& Co., Mountain View, CA). Tonsillar tissue was gently teased 
and the resulting cell suspension centrifuged over Histopaque  | 
T cells were purified as described for PB T cells. Purification of 
B cells was achieved  by removal  of  cells rosetting with AET-treated 
SRBC and treatment of the remaining cells with B cell lympho- 
1 Abbreviations used in this paper: AET, aminoethylisothiouronium bromide; 
FBS, fetal bovine serum;  PB T, peripheral blood T cells. 
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lyse contaminating non-B cells. The resultant B cell preparations 
were >96%  CD20 + as determined by flow cytometry. Murine 
splenic B cells were isolated using anti-T cell antibody and comple- 
ment, followed by passage over Sephadex C--10 (Pharmacia Fine 
Chemicals, Piscataway, NJ) to remove adherent cells. B cells were 
then positively sdected by panning on plates coated with 5 #g/m1 
goat anti-mouse  IgM (Southern Biotechnology Associates, Bir- 
mingham, AL). Isolated cells were >95% surface IgM + as deter- 
mined by flow cytometry. 
Reagents.  Murine and human recombinant II.-4 were purified 
from yeast superuatant as previously described (15). The 57-kD 
gene product of the extracellular domain of human CD40 fused 
to the Fc region of  human IgG1 (CD40.Fc) was expressed,  purified, 
and labeled with biotin-X-nonhydroxy succinimide (NHS; Calbio- 
chem Corp.,  La Jolla,  CA)  as previously described (16). CV1/ 
EBNA cells transfected with plasmids containing  the hCD40-L 
or mCD40-L (see below) as described (14, 17), were cultured for 
3 d on 10-cm petri dishes, removed and fixed with 1% parafor- 
maldehyde for 10 min at 40C, and washed extensively in culture 
medium before their use in biological assays. 
Culture Conditions.  For the preparation of RNA, PB T cells 
were activated for 20 h with immobilized CD3 mAb. Tonsil T cells 
were activated for 20 h with 10 ng/ml PMA and 1 #g/ml Con 
A. For proliferation assays, purified B cells (10VweU) were cultured 
in triplicate with a titration of CV1/EBNA cells expressing human 
or murine CD40 ligand in flat-bottomed 96-well microtiter plates 
in 200 #1 RPMI in a humidified atmosphere of 10% COs.  For 
the proliferation of murine B cells, medium was supplemented with 
5% heat-inactivated fetal bovine serum (FBS), 1 mM sodium pyru- 
rate, 0.1 mM nonessential amino acids, 100 U/ml penicillin, 100 
#g/ml streptomycin, 2 mM t-glutamine,  and 50 #M 2-ME. For 
human  B cells, medium was supplemented with 10% FBS, 100 
U/m1 penicillin, and 100 #g/ml streptomycin. Wells were pulsed 
with 2 #Ci [38]thymidine (25 Ci/mmol) for the final 8 h of cul- 
ture, cells were harvested, and incorporated cpm was determined 
by tritium-sensitive avalanche gas ionization detection on a beta 
counter (Matrix 96 Direct; Packard  Instrument Co., Inc., Meriden, 
CT). Cultures for the determination of murine IgE secretion were 
performed as described for murine B cell proliferation assays but 
in supplemented RPMI 1640 containing 20% FBS. Culture condi- 
tions for the determination of  human lgE were basically  as described 
for human B cell proliferation assays  but were conducted in round- 
bottomed 96-well microtiter plates. IgE levels in culture supema- 
tams were determined by ELISA and were sensitive to 100 pg/ml 
and 4 ng/ml of human  and murine  IgE, respectively. 
Flow Cytometric Analysis.  Purified human PB T cells (106/ml) 
were cultured with 10 #g/ml immobilized OKT3 (CD3, Amer- 
ican Type  Culture Collection) mAb in the presence or absence of 
10 ng/ml PMA for the times indicated. Cells were harvested and 
preincubated with 100 #g/nil human  IgG1 in PBS plus 0.02% 
NaN3  for 30  min  at  4~  to  prevent  nonspecific binding  of 
staining reagents. Surface expression of CD40-L was determined 
by staining with 5 #g/ml biotinylated CD40.Fc for 30 min at 4~ 
Cells were washed twice with PBS plus 0.02%  NaN~ and in- 
cubated for 30 min longer at 4~  with streptavidin-PE diluted 1:5 
in PBS plus 0.02% NaN3 and then analyzed using a FACScan  | 
(Becton Dickinson & Co.). A minimum of 5,000 cells were ana- 
lyzed for each sample. 
eDNA Library Construction.  Pooled human PB T were isolated 
from normal donors and cultured in 10 ng/ml IL-2  for 6 d followed 
by stimulation with 10 ng/ml PMA and 1 #g/ml Con A for 8 h. 
Polyadenylated  RNA was used as a template to construct a random 
primed eDNA library using a eDNA synthesis kit (Amersham 
Corp., Arlington Heights, IL). eDNA was adaptored using EcoRI 
linkers and cloned into a )~gtlI vector (Stratagene Inc., La Jolla, 
CA). The library was screened with a 3Zp-labeled  mCD40-L ribo- 
probe which was generated using SP6 polymerase (Promega Corp., 
Madison, WI) according to the supplier's protocol. This probe cor- 
responds to the complete coding region of the mCD40-L  gene, 
and was hybridized to the )~gt11 library at 55~  in Stark's solution 
followed by washing in 2  x  SSC 0.1% SDS at 63~ 
Transient Expression of hCD40-L in Mammalian Cells.  The coding 
region of the hCD40-L was cloned into the mammalian expres- 
sion vector pDC302 (17); DEAE transfections were performed in 
COS ceils as described  (18). Alternatively,  pDC302 expression  vector 
carrying the hCD40-L gene was cotransfected with the plasmid 
pSV3neo (19) using DEAE dextran into CV-1 EBNA cells (18). 
Northern Blot Analysis.  Northern blots were prepared essentially 
as described (20). Hybridization was performed in Stark's solution 
at 63~  followed by several washings in 0.2  x  SSC, 1% SDS at 
55~  Blots were exposed for 1-3 d at  -70~ 
Radiolabeting and Iraraunoprecipitations.  COS cells expressing the 
hCD40-L protein, or PB T cells cultured with immobilized CD3 
as described for 3 h were radiolabded with 100 #Ci/ml 3sS Tram- 
label (ICN Biomedicals, Inc., Irvine, CA) for 2-3 h. Cells were 
lysed in PBS containing 1% Triton X-100 and clarified at 10,000 g 
for 30 min. Lysates  were incubated with purified CD40.Fc protein 
(1 #g/ml) for 30 min followed by the addition of protein A-Seph- 
arose. After extensive washing, pellets were resuspended in sample 
buffer in the presence or absence of/J-ME and analyzed by PAGE. 
Resuks 
Characterization of the  hCD40-L  eDNA  Clone.  A  32p_ 
labeled riboprobe corresponding to the coding region of the 
mCD40-L was used to screen a stimulated human PB T  li- 
brary under reduced stringency (see Materials and Methods). 
This resulted in the isolation of a 1,803-bp eDNA that con- 
tained the complete coding region of the hCD40-L. This done 
contained a single open reading frame that could encode a 
polypeptide of 261  amino adds,  a 45-bp 5' noncoding re- 
gion, and 975 bp of Y noncoding sequences which included 
a poly(A) tail.  The predicted amino acid  sequence of the 
hCD40-L and an alignment with the CD40-L is shown in 
Fig. 1. Like the mCD40-L, the hCD40-L is a type II mem- 
brane protein with a short 22-amino acid NH2-terminal cy- 
toplasmic domain followed by a 24-amino acid hydrophobic 
signal anchor region. The hCD40-L has  a 215-amino acid 
COOH-terminal extracdlular domain compared to 214 amino 
acids in the mCD40-L and five  cysteine residues compared 
to four in the murine ligand. There is an N-linked glycosyla- 
tion site in the extracellular domain that is conserved between 
the human and murine ligands, and an additional, but likely 
not utilized, glycosylation site in the cytoplasmic domain of 
hCD40-L. The two sequences exhibit 78% amino acid iden- 
tity overall. More specifically, there is 81% amino acid iden- 
tity between the cytoplasmic domains,  96%  between the 
transmembrane regions, and 75% between the extracellular 
domains. 
Expression and Iraraunoprecipitation of  Recombinant hCD40-L. 
Oligonucleotide primers designed to include incompatible 
restriction  sites  were used in  a PCK reaction to  amplify 
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TGCCACCTTCTCTGC  CAGAAGATACCATTTCAACTTTAACACAGCATGATCGAAACATAC 
M  I  E  T  Y 
AACCAAACTTCTCC  C  CGATCTGCGGCCACTGGACTGC  CCATCAGCATGA~TTTTTATG 
S  P  R  S  A  A  T  G  L  P  I  S  M  K  I  F  M 
S  P  V  A 
TATTTACTTACTGTTTTTCTTATCACCCAGATGATTGGGTCAGCACTTTTTGCTGTGTAT 
Y  L  L  T  V  F  L  I  T  Q  M  I  G  S  A  L  F  A  V  Y 
60 
5 
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25 
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45 
240 
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480 
V 
CTTCATAGAAGGTTGGACAAGATAG~GATGA~GG~TCTTCATG~GATTTTGTATTC 
LHRRLDKIEDERNLHEDFVF 
V  E  V 
ATGAAAACGATACAGAGATGCAACACAGGAGAAAGATCCTTATCCTTACTGAACTGTGAG 
MKTIQRCNTGERSLSLLNCE 
I  KLK  K  G 
GAGATTAAAAGCCAGTTTGAAGGCTTTGTGAAGGATATAATGTTAAACA~GAGGAGACG 
EIKSQFEGFVKDIMLNKEET 
MRR  DL  T 
AAGAAAGAAAACAGCTTTGAAATGCAAAAAGGTGATCAGAATCCTCA~TTGCGGCACAT 
KKENSFEMQKGDQNPQIAAH 
R  ED 
GTCATAAGTGAGGCCAGCAGTAAAACAACATCTGTGTTACAGTGGGCTGAAA~GGATAC 
VISEASSKTTSVLQWAEKGY  145 
V  N  NAA  K 
TACACCATGAGCAACAACTTGGTAACCCTGGAAAATGGGAAACAGCTGACCGTTAA~GA  540 
YTMSNNLVTLENGKQLTVKR  165 
KS  M 
CAAGGACTCTATTATATCTATGCCCAAGTCACCTTCTGTTCCAATCGGGAAGCTTCGAGT  600 
QGLYYIYAQVTFCSNREASS  185 
E  V  T  P 
C~GCTCCATTTATAGCCAGCCTCTGCCTAAAGTCCCCCGGTAGATTCGAGAG~TCTTA  660 
QAPFIASLCLKSPGRFERIL  205 
R  VG  W  PSIGS 
CTCAGAGCTGCAAATACCCACAGTTCCGCCAAACCTTGCGGGCAACAATCCATTCACTTG  720 
LRAANTHSSAKPCGQQSIHL  225 
K  SQL  E  V 
GGAGGAGTATTTGAATTGCAACCAGGTGCTTCGGTGTTTGTCAATGTGACTGATCC~GC  780 
GGVFELQPGASVFV~DPS  245 
A  EA 
C~GTGAGCCATGGCACTGGCTTCACGTCCTTTGGCTTACTCAAACTCTGAACAGTGTCA  840 
QVSHGTGFTSFGLLKLQ  261 
I  RV  S 
CCTTGCAGGCTGTGGTGGAGCTGACGCTGGGAGTCTTCATAATACAGCACAGCGGTT~G  900 
CCCACCCCCTGTTAACTGCCTATTTATAACCCTAGGATCCTCCTTATGGAGAACTATTTA  960 
TTATACACTCCAAGGCATGTAGAACTGT~-A'~A'~TGAATTACAGGTCACATG~ACC~A  1020 
ACGGGCCCTGCTCCATAAGAGCTTATATATCTGAAGCAGCAACCCCACTGATGCAGACAT  1080 
CCAGAGAGTCCTATGAAAAGACAAGGCCATTATGCACAGGTTGAATTCTGAGTAAACAGC  1140 
AGAT~CTTGCC~GTTCAGTTTTGTTTCTTTGCGTGCAGTGTCTTTCCATGGATAATGC  1200 
ATTTGATTTATCAGTGAAGATGCAGAAGGGAAATGGGGAGCCTCAGCTCACATTCAGTTA  1260 
TGGTTGACTCTGGGTTCCTATGGCCTTGTTGGAGGGGGCCAGGCTCTAGAACGTCTAACA  1320 
CAGTGGAGAACCGAAACCCCCCCCCCCCCCCCGCCACCCTCTCGGACAGTTATTCATTCT  1380 
CTTTCAATCTCTCTCTCTCCATCTCTCTCTTTCAGTCTCTCTCTCTCAACCTCTTTCTTC  1440 
C~TCTCTCTTTCTCAATCTCTCTGTTTCCCTTTGTCAGTCTCTTCCCTCCCCCAGTCTC  1500 
TCTTCTCAATCCCCCTTTCTAACACACACACACACACACACACACACACACACACACACA  1560 
CACACACACACAGAGTCAGGCCGTTGCTAGTCAGTTCTCTTCTTTCCACCCTGTCCCTAT  1620 
CTCTACCACTATAGATGAGGGTGAGGAGTAGGGAGTGCAGCCCTGAGCCTGCCCACTCCT  1680 
CATTACGAAATGACTGTATTTAAAGGAAATCTATTGTATCTACCTGCAGTCTCCATTGTT  1740 
TCCAGAGTGAACTTGTAATTATCTTGTTATTTATTTTTTGAA~ATA~GACCTCTTAAC  1800 
ATT  1803 
Figure 1.  Nucleotide sequence exclusive of poly(A) 
of a cDNA encoding the hCD40-L protein (Genbank 
accession no. X67878). The predicted amino acid se- 
quence of hCD40-L is given and compared with that 
of mCD40-L. Amino acid differences are indicated. 
The putative NHz-terminal signal/anchor sequence is 
underlined, and potential N-linked glycosyhtion sites 
are  shaded. A  consensus  sequence  for  addition  of 
poly(A) is located at position 1784 (boxed), and a pos- 
sible alternative poly(A) site occurs at position 989 
(boxed). 
the coding region of the hCD40-L gene. After digestion with 
the appropriate enzymes, the resulting PCR product was sub- 
cloned into a mammalian expression vector. Sequence anal- 
},sis of the coding region insert confirmed that no nudeotide 
changes had occurred as a result of the PCK amplification. 
This plasmid  was  then used to  transfect COS cells.  The 
resulting  recombinant  hCD40-L  was  compared  with  the 
hCD40-L expressed on stimulated human PB T cells by meta- 
bolic labeling and precipitation using a previously described 
soluble CD40.Fc chimeric molecule (16). The results of this 
experiment  are shown in Fig.  2.  Immunoprecipitates  elec- 
trophoresed under reducing conditions (lane b) indicate an 
apparent Mr of 33-35  kD for the recombinant  hCD40-L. 
This protein comigrates with the hCD40-L protein derived 
from CD3 mAb-stimulated PB T  cells (lane d). Immuno- 
precipitates electrophoresed under nonreducing conditions are 
essentially indistinguishable (data not shown), suggesting that 
the hCD40-L does not dimerize through disulphide bonding. 
A larger band ("~ 69 kD) is present in the samples from stimu- 
lated PB T cells (lane d) or cells transfected with the hCD40-L 
(lane  b), but  not  in control  samples  (lanes c and e).  We 
addressed the possibility  that  this band  might be due to 
oligomerization of the ligand through noncovalent bond for- 
mation by electrophoresing precipitated samples on polyacryl- 
amide gels containing 7 M urea in the presence and absence 
of reducing agents. When these experiments are performed, 
1545  Spriggs et al. the results are similar to those in Fig. 2 (data not shown). 
Thus, the exact nature of the higher molecular weight mate- 
rial is still undear, but it is not likely to be a simple oligomer 
of the hCD40-L. 
Characterization of  hCD40-L Expression by Northern Blot Anal- 
yds.  Previously,  we reported that mCD40-L mKNA was 
induced in T cells activated with CD3 mAb (14). We exam- 
ined purified human PB T and tonsil T cells for their expres- 
sion of hCD40-L mKNA in response to various stimuli. Total 
RNA from PB T  cells activated with CD3 mAb, or tonsil 
T  cells stimulated with PMA and Con A, was analyzed on 
Northern blots  using a  32P-labeled antisense  KNA probe 
(Fig.  3).  No detectable hCD40-L was present in unstimu- 
lated PB T  or tonsil T  cell total RNA, but was inducible 
under both stimulation conditions. It is interesting that both 
PB T and tonsil T cells express what appear to be two hCD40- 
L-specific mKNAs. The larger band is typically  more promi- 
nent than the smaller band and appears to be ~2,000 bases 
in length, comparable to the size of the single mCD40-L 
mRNA seen  in murine T cells. The exact nature of the smaller 
band is unclear.  PCK experiments (our unpublished data) 
have not provided any evidence for alternate mRNA splicing. 
There is only a single AATAAA polyadenylation consensus 
sequence in the 3' noncoding region (Fig.  1). However, the 
sequence AATAAG appears at position 989 and might pos- 
sibly serve as an alternate polyadenylation signal. 
Cellular Distribution of the hCD40-L.  KNA was obtained 
from CD3 mAb-stimulated PB T cells and a number of call 
lines of myeloid, lymphoid, fibroblastic, and epithelial origin, 
and examined for hCD40-L transcripts. The following cell 
types were found negative by Northern blot analysis using 
5 #g poly(A) + KNA per lane:  Blin,  CB23,  Raji, Jurkat, 
PBM, monocytes, Thp-1, U937, HeLa, A549, placenta, and 
dermal fibroblasts.  After hybridization with the 32p-labeled 
antisense probe described above, no hCD40-L-specific mKNA 
could be detected in any cell type other than T cells or their 
derivatives.  In addition, we examined a commercially avail- 
able Northern blot containing total RNA derived from a va- 
riety of human tissues  (Fig.  4).  On this blot,  the radiola- 
baled hCD40-L probe hybridized with KNA derived from 
lung tissue.  This  was  somewhat  surprising based  on  the 
Figure  3.  Northern blot analysis of 
hCD40-L-expressing T  cells. Total KNA 
from stimulated  PB T or tonsil  T cells was 
analyzed on Northern blots using a 3zp. 
labeled antisense  hCD40-L  probe. Lanes:  (a) 
unstimulated  PB T cells; (b) CD3-stimulated 
PB T cells; and (c) PMA plus Con A-stimu- 
lated tonsil T cells. 
Northern blot analysis of specific cell KNAs. However, it 
was possible that the hCD40-L--specific mRNA in this lung 
sample was due to contaminating T lymphocytes. To address 
this, we rehybridized this tissue blot with a 32p-labeled an- 
tisense probe derived from the c5 chain of the TCR (Fig.  4 
B). This experiment resulted in the detection of a band of 
the expected size which was present exclusively in the lung- 
derived sample. Therefore, it appears that within the cell types 
examined thus far, expression  of the hCD40-L is restricted 
to T  lymphocytes. 
Induction of hCD40-L  on PB T  Cells.  The induction of 
hCD40-L expression on PB T cells was examined over 36 h 
after activation with CD3 antibody, PMA,  or a combina- 
Figure 2.  Precipitation  ofhCD40-L 
protein using  soluble  CD40.Fc. COS 
cells  expressing  the hCD40-L  protein 
or CD3 mAb-stimulated  PB T cells 
were radiolabeled  as described  in Ma- 
terials and Methods. Lysates  were 
precipitated  using  CD40.Fc and pro- 
tein A-Sepharose  and analyzed  under 
reducing conditions on an 8-16% 
polyacrylamide SDS  gradient gel. 
Lanes: (a) molecular  weight  markers; 
(b) recombinant  hCD40-L  protein  de- 
rived from transfected  cells; (c) cells 
transfected with empty vector; (d) 
hCD40-L  protein  from  stimulated  PB 
T cells; and  (e)  unstimulated PB 
T cells. 
Figure 4.  Northern blot analysis  of tissue-specific RNAs. Poly(A)  + 
RNA from  the indicated  tissues  was hybridized  with antisense  riboprobes 
as described  in Materials  and Methods. (.4) Northern  blot hybridized  with 
a radiolabeled  probe corresponding  to the coding  region  of the hCD40-L 
(B) The same Northern blot, partially  stripped and rehybridized  with a 
probe specific for the ~ chain of the TCK. 
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Figure 5.  Induction ofCD40 ligand expression on PB T cells. Purified 
peripheral blood T cells were activated for up to 36 h in the presence of 
5/zg/ml immobilized  CD3 mAb (O), 5 ng/ml PMA (ll), or a combina- 
tion of CD3 mAb plus PMA (O). Cells were harvested at the time indi- 
cated, stained with 5 #g/ml biotinylated CD40.Fc and streptavidin-PE, 
and analyzed by flow cytometry.  Results are expressed as the percent of 
cells positive for biotinylated CD40.Fc binding compared to cells stained 
with control hiotinylated  IL-4R.Fc. 
tion of the two (Fig. 5). Unstimulated T cells expressed vir- 
tually undetectable levels of hCD40-L, as determined  by flow 
cytometric analysis of  cells stained with biotinylated CD40.Fc. 
Treatment with CD3 mAb induced detectable hCD40-L by 
4 h, with maximal expression at 8-16 h, and with significant 
expression  still detected at  36  h.  Stimulation with PMA 
resulted in lower levels of ligand expression but similar ki- 
netics of induction. A combination of CD3 mAb and PMA 
induced detectable hCD40-L by 2 h and resulted in a higher 
level ofligand expression at 16 h than seen with either factor 
alone. In contrast to CD3 mAb, PHA alone was not an effec- 
tive inducer of hCD40-L, but in combination with PMA 
resulted in levels of ligand comparable to those seen with 
a combination of CD3 mAb and PMA (data not shown). 
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Figure 6.  CD40 ligand is induced predominantly on CD4 + T cells. 
Purified PB T cells were cukured for 16 h in medium (A and B) or acti- 
vated with 5/~g/ml immobilized CD3 mAb (C and D) and stained with 
biotinyhted CD40.Fc and streptavidin-PE  and either FITC-conjugated CD4 
(,4 and C) or CD8 (B and D) mAb. Results are representative from one 
of six experiments performed. 
Expression of hCD40-L on T Cell Subpopulations.  CD4* 
and CD8 +  PB T cells were examined for the expression of 
hCD40-L after 18-h stimulation with CD3 mAb (Fig. 6). 
In the absence of stimulation, CD4 + and CD8 + T cells ex- 
pressed no detectable hCD40-L as determined by binding of 
biotinylated CD40.Fc (Fig. 6, A and B). After treatment with 
CD3 mAb, hCD40-L expression was detected primarily on 
the CD4 + population (Fig. 6 C). However, a reproducible 
finding from experiments performed on T cells from many 
donors was that a small proportion of CD8 + T  cells was 
also induced to express hCD40-L (Fig. 6 D), although this 
expression was consistently lower than that seen on CD4 + 
cells. 
Induction of Proliferation with CD40-L.  The human and 
murine CD40-L were compared for their ability to mediate 
B cell proliferation.  Purified human tonsil B cells were in- 
duced to proliferate in the absence of added cytokines when 
cultured with fixed CV1/EBNA cells transfected with either 
human or murine CD40-L (Fig. 7 A). This effect appeared 
to be dose dependent. Addition of II.-4 to cultures enhanced 
the proliferative response of human B cells to both human 
and murine ligand. 
The effects of  hCD40-L on proliferation of murine splenic 
B cells was also examined (Fig. 7 B). As shown previously, 
mCD40-L was mitogenic in a dose-dependent  manner for 
murine B cells cultured in the absence of costimulus  (14). 
In contrast, under the same culture conditions, CV1/EBNA 
cells expressing the hCD40-L had virtually no effect. How- 
ever, the addition oflb4 to cultures containing the hCD40-L 
resulted in the proliferation of murine B cells. Although II.-4 
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Figure 7.  Comparative proliferative responses of B cells to human and 
murine CD40 ligand. (A) 10  s purified human tonsil B cells were cultured 
for 6 d with a titration of CV1/EBNA cells transfected with human (I, 
O) or murine (I,  D) CD40 ligand, in the presence (filled symbols) or 
absence (open symbols) of 5 ng/ml hIL-4. (/3) 10  s purified murine splenic 
B cells were cultured for 3 d with CD40 ligand as described above in the 
presence or absence of 10 ng/ml mIL-4. Results are expressed as mean in- 
corporated  cpm from triplicate cultures. 
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7 A), no such enhancement was observed when I1.-4 was added 
to routine B cell cultures containing mCD40-L (Fig. 7 B). 
In both human and routine proliferation assays, CV1/EBNA 
cells transfected with vector alone had no effect (13, data not 
shown). 
The two  forms  of  CD40-L were  compared  for  their  ability 
to  induce  IgE secretion  from ID4-activated  B cells.  Human 
and routine  CD40-L showed comparable  activity  in  the  in- 
duction  of  human IgE secretion  from purified  tonsil  B cells 
(Fig.  8  A). As  was seen  in  the  proliferation  assays,  this  effect 
also appeared dose dependent. Similarly,  both human and mu- 
rine forms of CD40-L induced IgE from Ib4-stimulated mu- 
fine splenic B cells (Fig. 7 B), although the human ligand 
appeared to exhibit  lower activity than the murine ligand 
in this assay. No secreted human or murine IgE was detected 
in the absence of IL-4 or if CV1/EBNA cells transfected with 
vector alone were used (14, data not shown). 
Discussion 
Cell surface molecules expressed on activated T cells that 
provide contact-dependent help to B cells have been the sub- 
ject of intense investigation.  Recently, a molecule expressed 
on CD3-activated  murine T  cells that induces B cells to 
proliferate in the absence of a costimulus and stimulates IgE 
secretion from Ib4-activated B cells was cloned and identified 
as a murine ligand for CD40 (14). Using crosshybridization 
techniques, we have isolated a human ligand for CD40 that 
exhibits  significant homology (78%  identity at the amino 
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Figure 8.  Human and murine IgE secretion induced by CD40 ligand. 
(el) 10  s purified human tonsil B cells were cultured for 10 d with a titra- 
tion of CV1/EBNA cells transfected with human (0) or murine (O) CD40 
ligand, in the presence of 5 ng/ml hlL-4, (B) l0  s purified murine splenic 
B cells were cultured for 7 d with CD40 ligand as described above in the 
presence of 10 ng/ml mlL-4. Results are expressed as mean values _+ SEM 
from triplicate  cultures. 
acid and 83% at the nudeotide levels) to its murine counter- 
part. This level of homology suggested that the hCD40-L 
would be active  on both murine and human B cells  in a manner 
similar to that described for mCD40-L (14). In terms of IgE 
secretion, this was indeed the case, although the hCD40-L 
displayed lower potency than the mCD40-L on murine B 
cells. However, with regard to induction of proliferation, we 
report significant differences  between the murine and human 
CD40-L. Using murine B cells, hCD40-L requires Ib4 for 
induction of proliferation, whereas mCD40-L does not. On 
the other hand, in the human B cell culture system both 
hCD40-L and mCD40-L are capable of inducing significant 
proliferation in the absence of Ib4. Moreover, II.-4 augments 
the response of human B cells to hCD40-L and mCD40-L. 
Experiments performed in our hboratory (unpublished data) 
indicate that human and murine B cells differ in the time at 
which the maximum proliferative  response to either hCD40-L 
or mCD40-L is observed. In routine B cell cultures, the max- 
imal proliferative response is seen at day 2, whereas human 
B cells show the highest rate of  proliferation at day 5, regardless 
of whether hCD40-L or mCD40-L is used as a stimulus. 
Because hCD40-L and mCD40-L have comparable activity 
on human B cells, the inability of hCD40-L to induce the 
proliferation  of murine B cells in the absence of II.-4 is in- 
triguing. One possible explanation for this disparity could 
be a decreased affinity of hCD40-L compared to mCD40-L 
for murine CD40. 
The predicted amino acid sequence for the murine CD40 
molecule is 62%  identical  to the human CD40 (2).  This 
level of homology might suggest that the binding of both 
mCD40-L and hCD40-L to either form of CD40 would be 
comparable. In support of this, we have previously shown 
that mCD40-L binds to human CD40 with high affinity (21). 
However,  additional  binding studies using hCD40-L  and 
mCD40-L will be necessary to further define this interaction. 
Another possible explanation for the disparity in the ac- 
tivity of the two ligands is that hCD40-L may not induce 
proliferation of murine B cells in the absence of costimulus 
unless the CD40 receptor molecule is being expressed at some 
required threshold level. It is known that CD40 is constitu- 
tively expressed on nonactivated human B cells at high levels 
relative to those observed on murine B cells (1, 2, 22, and 
our unpublished observations). The addition of IL-4 to acti- 
vated murine B cells enhances CD40 mRNA expression (2), 
which could result in an increased surface  expression suffident 
to allow the observed proliferative effects. Human B cells also 
respond to IL-4  by upregulating CD40 expression. However, 
if a minimum number or relative density of CD40 is required 
for optimal signaling, the comparable activity of hCD40-L 
and mCD40-L on human B cells in the absence of II.-4 may 
simply reflect the increased level of CD40 expression. In con- 
trast to the proliferation assays performed in the absence of 
a costimulus, the observation that hCD40-L and mCD40-L 
induce similar levels of IgE from murine B cells is likely due 
to the absolute requirement for 11,4 in secretion of  this isotype. 
The conformation of the ligands and the CD40 receptors 
no doubt play an important role in defming their relative 
1548  Human CD40 Ligand affinities for one mother. Fine structure epitope mapping using 
panels of mAbs will be useful, however,  as of yet, such re- 
agents are unavailable. Recently, Lederman et al. (23) described 
a mAb directed against a 30-kD activated T cell surface an- 
tigen which resembles the hCD40-L in its functional effects. 
This antibody inhibits the B cell proliferation and CD23 ex- 
pression induced by activated CD4 + T  cells. However, the 
kinetics of induction of the T cell surface antigen recognized 
by this antibody differ from that seen in our laboratory for 
the hCD40-L. In addition, reactivity of this antibody is re- 
stricted to CD4 + T cells, whereas hCD40-L can also be in- 
duced  on  a  small  percentage  of CD8 +  T  cells.  Further 
studies will be necessary to determine the exact identity of 
the T  cell antigen recognized by this antibody and its rela- 
tionship to the hCD40-L. 
The significance  of the induction of the hCD40-L on a 
small proportion of CD8 + PB T ceils is unclear.  Attempts 
to induce the expression of hCD40-L on human T cell clones 
(our unpublished observations) have thus far been successful 
only in  CD4 +  ceils,  despite  the  fact  that  several CD8 + 
clones have also been examined. Studies are currently underway 
to determine whether CD8 + cells expressing hCD40-L play 
a unique role in the normal immune response in vivo. 
In addition to B cells, the cellular distribution of CD40 
includes foUicular dendritic cells and epithdial cells. Given 
the diversity of the response  to B ceils to the CD40-L, it 
will be of interest in the future to determine the role of the 
CD40-L in the biology of other ceil types. 
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